Connect with us

Business

Trump’s South Korea tariff cuts are major boost for Hyundai and GM

Published

on

Trump’s South Korea tariff cuts are major boost for Hyundai and GM


American flags flutter outside a Hyundai automobile dealership in Irvine, California, U.S., March 27, 2025. 

Mike Blake | Reuters

DETROIT — Hyundai Motor and General Motors are set to be two of the greatest beneficiaries of lower U.S. tariffs on imports, including vehicles, from South Korea.

The South Korean-based automaker is the largest U.S. importer of new vehicles from the country, followed by GM. Both automakers have paid billions of dollars in levies so far this year after President Donald Trump placed 25% tariffs on imported vehicles from South Korea and other countries in the spring.

The Trump administration this past week confirmed plans to lower tariffs on certain products, including vehicles, to 15% from South Korea. A notice about the implementation of the trade deal was posted Wednesday on the Federal Register. Other countries such as Japan and the United Kingdom also have negotiated lower tariff rates with the Trump administration.

Prior to the reduction, Hyundai reported U.S. tariffs costed the company 1.8 trillion won ($1.2 billion) in the third quarter, up from 828 billion won ($565 million) in the previous quarter. GM most recently said its tariff impacts, largely from South Korea and Mexico, were expected to be between $3.5 billion and $4.5 billion in 2025.

GM CFO Paul Jacobson said Wednesday that the automaker initially expected tariffs on South Korean imports to cost $2 billion but that the company has been able to offset many of those costs. He said GM expects the levies to cost closer to $1 billion or less in 2026.

“We do think that is going to be a tailwind next year, just not as much as the whole 50% because the ultimate tariff bill that we’re going to pay this year for Korea was going to be a lot lower than the $2 billion from the stuff that we’ve been working on,” Jacobson said during a UBS conference.

The U.S. tariff announcement comes after South Korea officially introduced legislation in its parliament aiming to fulfill its promise to invest $350 billion for the U.S. over several years.

Hyundai Motor Group Executive Chair Euisun Chung delivers remarks, as U.S. President Donald Trump, U.S. House of Representatives Speaker Mike Johnson (R-LA) and Governor of Louisiana Jeff Landry stand, in the Roosevelt Room at the White House, in Washington, D.C., U.S., March 24, 2025. 

Carlos Barria | Reuters

“Korea’s commitment to American investment strengthens our economic partnership and domestic jobs and industry. We are also grateful for the deep trust between our two nations,” U.S. Commerce Secretary Howard Lutnick said in a statement posted Monday on X.

Hyundai North America CEO Randy Parker said the tariffs are still challenging but better than 25% as the automaker aims for a sixth-consecutive year of record U.S. retail sales in 2026.

“Fifteen percent is still 15%,” he told CNBC during a phone interview Tuesday. “Getting to 15% is a great milestone. It’s been quite the journey reaching this agreement, which has been, I would say, quite extensive.”

Hyundai, including its Kia subsidiary that operates separately in the U.S., has significantly increased its sales and operations in the U.S. in recent years. But the automaker continues to import the majority of its vehicles — estimated to be nearly 1 million units this year — from South Korea.

GlobalData estimates more than 1.37 million vehicles, or about 8.6% of the U.S. sales this year, will be vehicles that were imported from South Korea — making the country the largest exporter of American-sold vehicles aside from Mexico.

Hyundai is expected to import more than 951,000 vehicles in 2025, according to GlobalData. That includes more than 369,000 for Kia and 582,000 for Hyundai and its luxury Genesis brand.

Hyundai aims to have more than 80% of its U.S. vehicle sales be produced locally by 2030, the company said this year. That compares with roughly 40% currently. 

Despite the tariffs, GM is estimated to import nearly 422,000 vehicles from South Korea this year to the U.S., according to GlobalData. That would be a 3.6% increase compared with record imports of more than 407,000 units last year.

GM has increasingly used South Korean plants to produce popular entry-level crossovers for Chevrolet and Buick. Its U.S. sales of South Korean-produced vehicles — largely entry-level models — have risen from 173,000 in 2019 to more than 407,000 last year, according to GlobalData.

GM, in an emailed statement, said the company “appreciates that negotiators have finalized an agreement on trade between the US and South Korea.”

“GM’s long-standing Korea operations produce high-quality, affordable crossovers that complement our U.S. vehicles and domestic production, which will soon rise to 2 million units. We will be monitoring and reviewing the details,” GM said.

GM produces its Buick Encore GX and Buick Envista crossovers, as well as the Chevrolet Trailblazer and Chevrolet Trax crossovers, at plants in South Korea. The company has touted the vehicles as being a pinnacle for the automaker’s profitable growth in lower-margin, entry-level vehicles.

Detainees are made to stand against a bus before being handcuffed, during a raid by federal agents where about 300 South Koreans were among 475 people arrested at the site of a $4.3 billion project by Hyundai Motor and LG Energy Solution to build batteries for electric cars in Ellabell, Georgia, U.S. September 4, 2025 in a still image taken from a video.

U.s. Immigration And Customs Enf | Via Reuters

The new U.S.-South Korea trade deal comes months after a period of tension between the two countries following an immigration raid at a battery plant jointly owned by Hyundai and LG Energy Solution in Georgia.

About 475 workers, including more than 300 South Koreans, were arrested in the Sept. 4 raid at the plant in Ellabell, Georgia, according to U.S. immigration officials. 



Source link

Business

How Costly Is A $10 Oil Spike For India’s Economy?

Published

on

How Costly Is A  Oil Spike For India’s Economy?


Last Updated:

Every $10 rise in global crude oil prices could shave around 0.5 percentage points off India’s GDP growth, say experts

India imports nearly 50 percent of crude oil from the Middle East

India imports nearly 50 percent of crude oil from the Middle East

Every $10 rise in global crude oil prices could shave around 0.5 percentage points off India’s GDP growth, underscoring the country’s heavy reliance on imported oil and vulnerability to global energy volatility, Vandana Bharti, Research Head–Commodity at SMC Global Securities, told ANI.

In an interview with ANI, Bharti said escalating geopolitical tensions in West Asia pose a significant economic risk for India as crude prices climb and supply chains face potential disruptions.

“Every $10 increase in crude oil prices impacts India’s GDP by roughly 0.5%. We have already seen prices rise by about $10–$15 recently, and the economic impact will eventually reflect in growth numbers,” she said.

West Asia tensions driving oil prices higher

The surge in oil prices follows intensifying tensions involving the United States, Israel and Iran, particularly around the Strait of Hormuz — a critical maritime corridor through which roughly 20–25% of global oil shipments pass.

Bharti said the conflict has injected additional uncertainty into global energy markets and added what she described as a “war premium” to crude prices.

“It’s not just about the possibility of the Strait of Hormuz closing. Insurance costs and freight charges are rising, and shipments are being rerouted. All these factors add a war premium to crude oil prices and increase market uncertainty,” she said.

Risks extend beyond shipping

According to Bharti, the risks go beyond maritime routes and extend to energy infrastructure itself.

“Energy sites such as crude oil facilities and LNG plants are potential targets. There are also concerns about seabed cables and other critical infrastructure. So the threat is not only to energy supply but also to broader global trade and connectivity,” she noted.

Crude prices rise sharply

Oil prices have already surged as tensions intensified in the region.

Bharti said crude climbed from around $69 per barrel to nearly $78 per barrel within a week.

“In just one week we have seen prices move from about $69 to $78 per barrel. If tensions persist, crude could rise further to around $85–$87 per barrel in the coming days,” she said.

India’s reliance on Middle Eastern crude

India remains particularly vulnerable to such price shocks due to its heavy dependence on imported oil.

Bharti noted that roughly half of India’s crude imports come from the Middle East, and many domestic refineries are specifically configured to process Middle Eastern crude grades.

“India imports nearly 50% of its crude from the Middle East, so any disruption in the region directly impacts supply availability and pricing,” she said.

India maintains strategic petroleum reserves that can help cushion short-term disruptions, but Bharti emphasised that these are primarily meant for emergencies.

“We have reserves that can last about 25–30 days in emergency situations, but the structural dependence on Middle Eastern supply remains,” she said.

She added that even brief supply disruptions could trigger volatility across Asian financial markets.

“Even a two-week disruption could create significant volatility in Asia. We are already seeing pressure on currencies, equity outflows and rising economic uncertainty,” Bharti said.

Diversification may cushion the impact

Bharti said India could mitigate some risks by diversifying crude supply sources.

“Russia has been offering crude at discounted prices, so India may increase purchases from Russia or other suppliers if required. Adjusting supply chains and renegotiating trade arrangements can provide some relief,” she said.

She also pointed out that members of the Organization of the Petroleum Exporting Countries (OPEC) may attempt to stabilise prices, although security concerns could limit immediate production increases.

Impact on fertilisers and agriculture

Higher crude prices could also ripple into other sectors of the economy.

Bharti warned that rising energy costs may push up fertiliser prices and agricultural input costs, potentially affecting the upcoming kharif crop season.

“Higher energy costs could make fertilisers and farm inputs more expensive, which may increase the cost of cultivation for farmers,” she said.

Renewables gain strategic importance

Bharti added that the ongoing geopolitical tensions highlight the need for countries to accelerate the transition to renewable energy.

“Events like this are a wake-up call. Governments may increasingly prioritise renewable energy such as solar to reduce dependence on volatile fossil-fuel supply routes,” she said.

Click here to add News18 as your preferred news source on Google.

Check Iran Israel War News Today Live Updates.

Follow News18 on Google. Join the fun, play games on News18. Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the News18 App to stay updated.

Disclaimer: Comments reflect users’ views, not News18’s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Read More



Source link

Continue Reading

Business

Anthropic officially designated a supply chain risk by Pentagon

Published

on

Anthropic officially designated a supply chain risk by Pentagon



The supply chain risk designation of the artificial intelligence firm is a first for a US company.



Source link

Continue Reading

Business

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

Published

on

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease


Thomas Fuller | SOPA Images | Lightrocket | Getty Images

UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.

The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.

“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”

The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.

UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.

The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”

UniQure didn’t immediately comment.

The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.



Source link

Continue Reading

Trending